...Type: Venture financing Raised: $43 million Investors: F2 Biosciences; Biotech Growth; MPM Capital; Brookside Capital; MPM Bio IV NVS Strategic Fund...

...round led by new investor F2 Biosciences. Existing investors Biotech Growth; MPM Capital; Brookside Capital; MPM Bio IV NVS Strategic Fund...

...Raised: $22 million Investors: BB Biotech AG; Brookside Capital; Saints Capital; Nordic Bioscience; Ipsen S.A.; MPM Bio IV NVS Strategic Fund...

...firms, including CMEA Capital (see BioCentury, Sept. 13). MPM Capital manages the Novartis option fund, MPM Bio IV NVS Strategic Fund...

...and cardiovascular play Aires Pharmaceuticals Inc. will be the last deal out of its first MPM Bio IV NVS Strategic Fund...

...in a series B round led by new investor MPM Capital on behalf of the MPM Bio IV NVS Strategic Fund...

...Diego, Calif. Business: Cardiovascular, Pulmonary Date completed: 11/11/10 Type: Venture financing Raised: $20 million Investors: MPM Bio IV NVS Strategic Fund...

...details were not disclosed. New investor MPM Capital led the round on behalf of the MPM Bio IV NVS Strategic Fund...

...$12 million in a series B2 round led by MPM Capital on behalf of the MPM Bio IV NVS Strategic Fund...

...and you just can't get that kind of money now," said Foley, who manages the MPM Bio IV NVS Strategic Fund...